Cost-benefit rulings ahead at Germany's Gemeinsame Bundesausschuss:
This article was originally published in Clinica
Germany's Gemeinsame Bundesausschuss (G-BA), the joint federal committee that decides whether healthcare products are reimbursable, used cost-benefit analysis for the first time this week in coming to a decision on genetically-engineered insulin analog. So reported FT Deutschland, of a decision that will resonate not just throughout the pharma sector, but will have implications for device manufacturers too. In declining reimbursement of the product for all but exceptional cases, the G-BA followed the 2004 recommendation of its executive arm, the IQWiG. Its decision effectively said that the benefits for type-2 diabetes sufferers do not match the euro30m ($38m) spent annually on the medication. It will now be used only when it is not more expensive than conventional human insulin (it is currently at a premium of 30-60%). There are 250,000 sufferers of type-2 diabetes in Germany. IQWiG will doubtless feel empowered by the public vindication of its decision; more evaluations (for asthma and high blood pressure, etc) lie ahead.